Please assess the completion status of the following clinical trial:

Trial Title: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following cellular types:~  * Grade III follicular center~ * Diffuse large B-cell~ * Mantle cell~ * Primary mediastinal B-cell~ * Burkitt's~ * High-grade B-cell (Burkitt-like)~ * Anaplastic large cell of 1 of the following subtypes:~    * CD30-positive~   * T-cell~   * Null cell~   * Hodgkin's-like~* Relapsed or refractory disease after prior standard chemotherapy, meeting criteria for 1of the following cohorts:~  * Cohort 1 (relapsed but chemosensitive): Prior complete response (CR) or partial response (PR) lasting at least 4 weeks after the most recent prior therapy~ * Cohort 2 (refractory): Stable disease or less than a PR after the most recent prior therapy~    * No progressive disease after the most recent prior therapy~* Measurable disease~  * At least 1 bidimensionally measurable lesion at least 10 mm by conventional techniques or clinical exam~* Ineligible for or unwilling to undergo hematopoietic stem cell transplantation~  * Patients requiring debulking prior to transplant allowed~* No known CNS involvement by lymphoma~  * Prior CNS disease that has been successfully treated in patients with relapsed disease exclusively outside of the CNS may be allowed by the principal investigator~* Performance status - ECOG 0-2~* More than 3 months~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,200/mm\^3~* Platelet count at least 100,000/mm\^3~* Bilirubin no greater than 1.5 mg/dL~* AST/ALT no greater than 2.5 times upper limit of normal~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prior allergic reaction or hypersensitivity to compounds containing Cremophor EL or agents of similar chemical or biological composition to BMS-247550~* No peripheral neuropathy grade 2 or greater~* No other currently active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix (previously treated malignancy allowed if considered to be at less than 30% risk of relapse)~* No ongoing or active infection~* No psychiatric illness or social situation that would preclude study compliance~* No other concurrent uncontrolled illness~* No colony-stimulating factors (CSFs) within 24 hours of study chemotherapy~* No CSFs during first course of study therapy~* No concurrent filgrastim-SD/01~* No concurrent immunotherapy~* See Disease Characteristics~* At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin)~* No other concurrent chemotherapy~* No concurrent hormonal therapy~* At least 4 weeks since prior radiotherapy~* No concurrent therapeutic radiotherapy~* At least 4 weeks since prior surgery~* Recovered from prior therapy~* At least 7 days since prior cimetidine~* No concurrent cimetidine~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent investigational agents~* No other concurrent anticancer medications~* No concurrent unconventional therapies, food, or vitamin supplements containing Hypericum perforatum

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy) (Type: EXPERIMENTAL): Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).